STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4031 by analyst upside · 2026-08-12
PRCT
PROCEPT BioRobotics Corporation
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
-5.5%
implied upside to consensus target
Current Price $22.89
Consensus Target $21.64
Bull Target $28.0
Bear Target $16.0
Analysts Covering 11
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
2
Hold
7
Sell
1
52-Week Low $16.66
52-Week High $42.7
YTD Return -25.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.95
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $337M
Profit Margin -32.5%
52-WEEK RANGE
52-Week Low $16.66
52-Week High $42.7
Current Price $22.89
Bear Target $16.0
Bull Target $28.0
● Now $22.89 ● Target $21.64
TRADING DATA
Avg Volume 1.7M
YTD Return -25.6%
Analyst Count 11
Consensus Hold
Upside to Target -5.5%
Last Updated 2026-08-12

ANALYST SUMMARY

PROCEPT BioRobotics Corporation (PRCT) is currently trading at $22.89 with a Wall Street consensus price target of $21.64, which is 5.5% below the current price over the next 12 months. 11 analysts currently cover PRCT, with a consensus rating of Hold - 27% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $16.0.

PRCT operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 25.6% year-to-date and is currently trading near the lower end of its 52-week range of $16.66 – $42.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-06-11 29% win rate (7 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-30 14% win rate (7 calls)
Baird ● Initiated
Neutral 2026-03-06 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-03-02 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-02-26 29% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-02-26 Building track record
Oppenheimer ↓ Downgrade
Outperform → Perform 2026-02-26 14% win rate (7 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-02-26 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
19/30
Consensus clarity
20/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →